Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ceramides | 40 | 2018 | 578 | 2.810 |
Why?
|
Antineoplastic Agents | 14 | 2020 | 1070 | 1.360 |
Why?
|
Photochemotherapy | 4 | 2022 | 59 | 1.140 |
Why?
|
Enzyme Inhibitors | 8 | 2020 | 659 | 1.010 |
Why?
|
Acid Ceramidase | 9 | 2020 | 85 | 0.980 |
Why?
|
Ceramidases | 8 | 2020 | 47 | 0.970 |
Why?
|
Propanolamines | 7 | 2017 | 70 | 0.880 |
Why?
|
Acetates | 1 | 2020 | 74 | 0.710 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 53 | 0.700 |
Why?
|
Amines | 1 | 2020 | 98 | 0.690 |
Why?
|
Sphingolipids | 11 | 2020 | 337 | 0.600 |
Why?
|
Amides | 7 | 2014 | 86 | 0.590 |
Why?
|
Sphingosine | 10 | 2017 | 315 | 0.560 |
Why?
|
Apoptosis | 13 | 2020 | 1641 | 0.550 |
Why?
|
Cell Line, Tumor | 22 | 2020 | 1851 | 0.460 |
Why?
|
Myristates | 3 | 2008 | 21 | 0.450 |
Why?
|
Cell Membrane | 6 | 2018 | 525 | 0.450 |
Why?
|
Alkaline Ceramidase | 7 | 2010 | 35 | 0.390 |
Why?
|
Amidohydrolases | 6 | 2007 | 60 | 0.390 |
Why?
|
Pyridinium Compounds | 5 | 2013 | 40 | 0.390 |
Why?
|
Drug Screening Assays, Antitumor | 4 | 2020 | 111 | 0.340 |
Why?
|
Mitochondria | 6 | 2016 | 643 | 0.330 |
Why?
|
Chromatography, High Pressure Liquid | 8 | 2016 | 381 | 0.320 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2019 | 346 | 0.290 |
Why?
|
Cell Death | 6 | 2018 | 329 | 0.290 |
Why?
|
Animals | 28 | 2022 | 20881 | 0.270 |
Why?
|
Nitrobenzenes | 2 | 2017 | 13 | 0.270 |
Why?
|
Protein Phosphatase 2 | 2 | 2019 | 67 | 0.270 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2018 | 30 | 0.270 |
Why?
|
Prodrugs | 2 | 2017 | 54 | 0.260 |
Why?
|
Mitochondrial Membranes | 4 | 2015 | 45 | 0.260 |
Why?
|
Tandem Mass Spectrometry | 5 | 2016 | 139 | 0.240 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 8 | 2010 | 67 | 0.240 |
Why?
|
Cell Proliferation | 5 | 2020 | 1174 | 0.240 |
Why?
|
Galactosylgalactosylglucosylceramidase | 4 | 2008 | 39 | 0.240 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2017 | 629 | 0.240 |
Why?
|
Humans | 51 | 2022 | 68618 | 0.230 |
Why?
|
Mice | 12 | 2022 | 8474 | 0.230 |
Why?
|
Stereoisomerism | 6 | 2010 | 169 | 0.220 |
Why?
|
RNA, Small Interfering | 7 | 2016 | 434 | 0.220 |
Why?
|
Protein Processing, Post-Translational | 3 | 2017 | 284 | 0.220 |
Why?
|
Tumor Cells, Cultured | 5 | 2020 | 852 | 0.210 |
Why?
|
Cell Nucleus | 3 | 2018 | 305 | 0.210 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 3 | 2017 | 201 | 0.210 |
Why?
|
Inflammasomes | 1 | 2022 | 39 | 0.210 |
Why?
|
Myeloid-Derived Suppressor Cells | 1 | 2022 | 21 | 0.200 |
Why?
|
Ion Channels | 2 | 2012 | 72 | 0.200 |
Why?
|
Fingolimod Hydrochloride | 2 | 2019 | 24 | 0.190 |
Why?
|
Radiation Tolerance | 1 | 2020 | 30 | 0.190 |
Why?
|
Structure-Activity Relationship | 4 | 2017 | 420 | 0.190 |
Why?
|
Golgi Apparatus | 5 | 2010 | 75 | 0.180 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 231 | 0.180 |
Why?
|
Neoplasms | 4 | 2022 | 1667 | 0.180 |
Why?
|
Oxidative Stress | 3 | 2018 | 718 | 0.180 |
Why?
|
Arthritis, Experimental | 1 | 2020 | 38 | 0.180 |
Why?
|
Rectal Neoplasms | 1 | 2020 | 75 | 0.180 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 77 | 0.180 |
Why?
|
Necrosis | 2 | 2018 | 239 | 0.180 |
Why?
|
Antigen Presentation | 1 | 2020 | 76 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 174 | 0.170 |
Why?
|
HeLa Cells | 8 | 2018 | 237 | 0.170 |
Why?
|
Autophagy | 2 | 2012 | 208 | 0.170 |
Why?
|
Lung Neoplasms | 3 | 2018 | 1173 | 0.170 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2019 | 33 | 0.160 |
Why?
|
Melanoma | 1 | 2022 | 335 | 0.160 |
Why?
|
Multiple Sclerosis | 1 | 2020 | 132 | 0.160 |
Why?
|
Molecular Motor Proteins | 1 | 2018 | 14 | 0.160 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 186 | 0.160 |
Why?
|
Myosin Heavy Chains | 1 | 2018 | 49 | 0.160 |
Why?
|
A549 Cells | 4 | 2019 | 50 | 0.160 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2017 | 626 | 0.160 |
Why?
|
Substrate Specificity | 9 | 2011 | 234 | 0.150 |
Why?
|
Prostatic Neoplasms | 3 | 2017 | 778 | 0.150 |
Why?
|
Benzimidazoles | 2 | 2016 | 128 | 0.150 |
Why?
|
Myristic Acid | 1 | 2017 | 6 | 0.150 |
Why?
|
Phosphotransferases | 1 | 2017 | 16 | 0.150 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2017 | 26 | 0.150 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2017 | 13 | 0.150 |
Why?
|
Mitochondria, Heart | 1 | 2018 | 53 | 0.150 |
Why?
|
Acyltransferases | 1 | 2017 | 40 | 0.150 |
Why?
|
Molecular Structure | 5 | 2015 | 397 | 0.150 |
Why?
|
Cell Cycle | 4 | 2007 | 312 | 0.150 |
Why?
|
Mitochondria, Liver | 3 | 2015 | 148 | 0.150 |
Why?
|
Guanidines | 1 | 2017 | 32 | 0.150 |
Why?
|
Stress, Physiological | 1 | 2018 | 215 | 0.140 |
Why?
|
Sphingosine N-Acyltransferase | 1 | 2017 | 62 | 0.140 |
Why?
|
Dextran Sulfate | 1 | 2017 | 88 | 0.140 |
Why?
|
Cations | 5 | 2011 | 51 | 0.140 |
Why?
|
Protein Binding | 7 | 2019 | 1027 | 0.140 |
Why?
|
Oligodendroglioma | 1 | 2016 | 18 | 0.140 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 21 | 0.140 |
Why?
|
Cell Division | 6 | 2010 | 541 | 0.140 |
Why?
|
Cisplatin | 1 | 2017 | 192 | 0.140 |
Why?
|
Cancer Vaccines | 1 | 2016 | 61 | 0.130 |
Why?
|
Models, Molecular | 3 | 2012 | 546 | 0.130 |
Why?
|
Piperidines | 1 | 2016 | 123 | 0.130 |
Why?
|
Caspases | 4 | 2012 | 194 | 0.130 |
Why?
|
Colitis | 1 | 2017 | 156 | 0.130 |
Why?
|
Interferon-gamma | 1 | 2016 | 241 | 0.130 |
Why?
|
Lysophospholipids | 3 | 2006 | 209 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 116 | 0.130 |
Why?
|
bcl-2-Associated X Protein | 2 | 2012 | 111 | 0.130 |
Why?
|
Myocytes, Cardiac | 1 | 2018 | 442 | 0.120 |
Why?
|
Blotting, Western | 7 | 2012 | 954 | 0.120 |
Why?
|
Rats | 9 | 2015 | 5300 | 0.120 |
Why?
|
Integrin beta1 | 3 | 2010 | 48 | 0.120 |
Why?
|
Phosphorylation | 5 | 2017 | 1200 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 332 | 0.120 |
Why?
|
Drug Design | 1 | 2014 | 107 | 0.120 |
Why?
|
Mice, SCID | 4 | 2017 | 238 | 0.110 |
Why?
|
Neutral Ceramidase | 2 | 2011 | 27 | 0.110 |
Why?
|
Cell Line | 4 | 2020 | 1752 | 0.110 |
Why?
|
Mutation | 2 | 2016 | 1213 | 0.110 |
Why?
|
Breast Neoplasms | 2 | 2017 | 1536 | 0.110 |
Why?
|
Histone Chaperones | 1 | 2012 | 11 | 0.110 |
Why?
|
Membrane Proteins | 1 | 2017 | 617 | 0.110 |
Why?
|
Propylene Glycols | 1 | 2012 | 16 | 0.110 |
Why?
|
Fenretinide | 2 | 2010 | 26 | 0.110 |
Why?
|
Proteome | 1 | 2013 | 87 | 0.110 |
Why?
|
Phagosomes | 1 | 2012 | 19 | 0.110 |
Why?
|
Endoplasmic Reticulum | 4 | 2010 | 148 | 0.100 |
Why?
|
Insulin-Secreting Cells | 1 | 2012 | 41 | 0.100 |
Why?
|
Neurilemmoma | 1 | 2012 | 26 | 0.100 |
Why?
|
NADPH Oxidases | 1 | 2012 | 80 | 0.100 |
Why?
|
Cell Survival | 4 | 2020 | 901 | 0.100 |
Why?
|
Group IV Phospholipases A2 | 2 | 2008 | 7 | 0.100 |
Why?
|
Enzyme Activation | 6 | 2012 | 791 | 0.100 |
Why?
|
Interferon Regulatory Factors | 1 | 2011 | 24 | 0.100 |
Why?
|
Oxidoreductases | 2 | 2013 | 117 | 0.100 |
Why?
|
Signal Transduction | 3 | 2016 | 2689 | 0.100 |
Why?
|
Keratinocytes | 2 | 2010 | 68 | 0.090 |
Why?
|
Combinatorial Chemistry Techniques | 2 | 2007 | 25 | 0.090 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 63 | 0.090 |
Why?
|
Growth Inhibitors | 1 | 2010 | 33 | 0.090 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 85 | 0.090 |
Why?
|
Mass Spectrometry | 3 | 2007 | 284 | 0.090 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 370 | 0.090 |
Why?
|
Head and Neck Neoplasms | 2 | 2006 | 561 | 0.090 |
Why?
|
Time Factors | 5 | 2010 | 4655 | 0.090 |
Why?
|
Cytochromes c | 4 | 2012 | 75 | 0.080 |
Why?
|
Telomerase | 3 | 2005 | 85 | 0.080 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 332 | 0.080 |
Why?
|
Helplessness, Learned | 1 | 2008 | 9 | 0.080 |
Why?
|
Proteins | 1 | 2012 | 474 | 0.080 |
Why?
|
Transcription Factors | 1 | 2012 | 753 | 0.080 |
Why?
|
Rats, Sprague-Dawley | 4 | 2015 | 2083 | 0.070 |
Why?
|
Calcium | 2 | 2010 | 929 | 0.070 |
Why?
|
Up-Regulation | 4 | 2013 | 682 | 0.070 |
Why?
|
Endothelial Cells | 1 | 2010 | 384 | 0.070 |
Why?
|
Capsid Proteins | 1 | 2006 | 27 | 0.070 |
Why?
|
Solubility | 1 | 2006 | 134 | 0.070 |
Why?
|
Brain | 2 | 2011 | 2176 | 0.070 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2006 | 8 | 0.070 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2006 | 19 | 0.070 |
Why?
|
Drug Synergism | 3 | 2017 | 260 | 0.070 |
Why?
|
Neuroblastoma | 1 | 2007 | 109 | 0.070 |
Why?
|
Genetic Therapy | 1 | 2008 | 291 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2012 | 304 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2006 | 90 | 0.060 |
Why?
|
Phosphatidylcholines | 1 | 2005 | 38 | 0.060 |
Why?
|
Phospholipases A | 1 | 2005 | 41 | 0.060 |
Why?
|
Hippocampus | 1 | 2008 | 471 | 0.060 |
Why?
|
Lysosomes | 3 | 2014 | 136 | 0.060 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenase (NADP+)(Phosphorylating) | 1 | 2003 | 4 | 0.060 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2003 | 67 | 0.060 |
Why?
|
Microscopy, Confocal | 3 | 2012 | 337 | 0.060 |
Why?
|
Gene Expression Regulation, Enzymologic | 3 | 2010 | 282 | 0.050 |
Why?
|
Cell Extracts | 1 | 2003 | 21 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2017 | 2673 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2017 | 2550 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 468 | 0.050 |
Why?
|
Down-Regulation | 3 | 2010 | 447 | 0.050 |
Why?
|
Membrane Potential, Mitochondrial | 2 | 2012 | 93 | 0.050 |
Why?
|
Hydrolysis | 3 | 2010 | 144 | 0.050 |
Why?
|
Microscopy, Electron | 3 | 2008 | 351 | 0.050 |
Why?
|
Protein Transport | 3 | 2008 | 280 | 0.050 |
Why?
|
Hydrogen-Ion Concentration | 3 | 2011 | 618 | 0.050 |
Why?
|
Male | 8 | 2020 | 37321 | 0.050 |
Why?
|
Depression | 1 | 2008 | 943 | 0.050 |
Why?
|
Flow Cytometry | 3 | 2010 | 489 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2007 | 710 | 0.050 |
Why?
|
Organoids | 1 | 2020 | 42 | 0.050 |
Why?
|
X-Rays | 1 | 2020 | 56 | 0.050 |
Why?
|
CRISPR-Cas Systems | 1 | 2020 | 41 | 0.050 |
Why?
|
HLA-DR4 Antigen | 1 | 2020 | 11 | 0.050 |
Why?
|
Models, Biological | 2 | 2020 | 981 | 0.050 |
Why?
|
Cathepsins | 1 | 2020 | 37 | 0.050 |
Why?
|
Gene Editing | 1 | 2020 | 33 | 0.050 |
Why?
|
Mice, Inbred DBA | 1 | 2020 | 120 | 0.050 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
Chromatography, Liquid | 2 | 2012 | 120 | 0.040 |
Why?
|
Fas Ligand Protein | 2 | 2011 | 64 | 0.040 |
Why?
|
Lipids | 2 | 2012 | 298 | 0.040 |
Why?
|
Deoxycytidine | 2 | 2012 | 83 | 0.040 |
Why?
|
Reference Standards | 2 | 2010 | 115 | 0.040 |
Why?
|
Dimerization | 1 | 2019 | 99 | 0.040 |
Why?
|
Caspase 3 | 2 | 2012 | 233 | 0.040 |
Why?
|
Transfection | 3 | 2006 | 782 | 0.040 |
Why?
|
Oogenesis | 1 | 2018 | 10 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 24 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2002 | 475 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
Permeability | 2 | 2012 | 131 | 0.040 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2018 | 55 | 0.040 |
Why?
|
HCT116 Cells | 1 | 2018 | 63 | 0.040 |
Why?
|
Hep G2 Cells | 1 | 2018 | 68 | 0.040 |
Why?
|
Molecular Docking Simulation | 1 | 2018 | 78 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2020 | 329 | 0.040 |
Why?
|
Ovary | 1 | 2018 | 99 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 89 | 0.040 |
Why?
|
Drosophila melanogaster | 1 | 2018 | 80 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2022 | 597 | 0.040 |
Why?
|
Amino Acid Sequence | 3 | 2006 | 1083 | 0.040 |
Why?
|
Calibration | 2 | 2009 | 73 | 0.040 |
Why?
|
Desipramine | 2 | 2008 | 47 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2011 | 532 | 0.040 |
Why?
|
Ligands | 1 | 2018 | 317 | 0.040 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 137 | 0.040 |
Why?
|
Chemokine CXCL2 | 1 | 2017 | 13 | 0.040 |
Why?
|
Molecular Sequence Data | 3 | 2006 | 1447 | 0.040 |
Why?
|
Chemokine CXCL1 | 1 | 2017 | 21 | 0.040 |
Why?
|
Heterografts | 1 | 2017 | 70 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2017 | 160 | 0.040 |
Why?
|
Tamoxifen | 1 | 2017 | 62 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 2012 | 499 | 0.040 |
Why?
|
Isoenzymes | 2 | 2011 | 308 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2017 | 112 | 0.040 |
Why?
|
Dynamins | 1 | 2016 | 14 | 0.040 |
Why?
|
Macrophages | 1 | 2020 | 647 | 0.030 |
Why?
|
Gene Expression Regulation | 2 | 2017 | 1293 | 0.030 |
Why?
|
GTP Phosphohydrolases | 1 | 2016 | 46 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2017 | 326 | 0.030 |
Why?
|
Extracellular Vesicles | 1 | 2016 | 21 | 0.030 |
Why?
|
Membrane Potentials | 2 | 2007 | 200 | 0.030 |
Why?
|
DNA Primers | 2 | 2007 | 302 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2017 | 194 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 138 | 0.030 |
Why?
|
Exosomes | 1 | 2016 | 44 | 0.030 |
Why?
|
Immunomodulation | 1 | 2016 | 35 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
Oligodendroglia | 1 | 2016 | 107 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2016 | 113 | 0.030 |
Why?
|
Microtubule-Associated Proteins | 1 | 2016 | 114 | 0.030 |
Why?
|
Cell Adhesion | 2 | 2008 | 324 | 0.030 |
Why?
|
RNA Interference | 2 | 2007 | 266 | 0.030 |
Why?
|
Chronic Disease | 1 | 2020 | 1330 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 126 | 0.030 |
Why?
|
Female | 4 | 2020 | 38074 | 0.030 |
Why?
|
Erythrocytes | 1 | 2015 | 137 | 0.030 |
Why?
|
Sphingomyelin Phosphodiesterase | 2 | 2007 | 183 | 0.030 |
Why?
|
Esters | 1 | 2014 | 22 | 0.030 |
Why?
|
MCF-7 Cells | 1 | 2014 | 80 | 0.030 |
Why?
|
Plasmids | 2 | 2006 | 258 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2010 | 1664 | 0.030 |
Why?
|
Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 951 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2017 | 7029 | 0.030 |
Why?
|
Base Sequence | 2 | 2007 | 1015 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 129 | 0.030 |
Why?
|
Phenotype | 1 | 2016 | 947 | 0.030 |
Why?
|
Carbocyanines | 1 | 2012 | 13 | 0.030 |
Why?
|
NADPH Oxidase 2 | 1 | 2012 | 16 | 0.030 |
Why?
|
Bromides | 1 | 2012 | 17 | 0.030 |
Why?
|
Nitrophenols | 1 | 2012 | 14 | 0.030 |
Why?
|
Spectrum Analysis | 1 | 2012 | 81 | 0.030 |
Why?
|
Coloring Agents | 1 | 2012 | 66 | 0.030 |
Why?
|
Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2013 | 250 | 0.030 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 77 | 0.030 |
Why?
|
Aniline Compounds | 1 | 2012 | 52 | 0.030 |
Why?
|
Glioma | 1 | 2013 | 140 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 247 | 0.030 |
Why?
|
Horses | 1 | 2012 | 20 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2012 | 196 | 0.030 |
Why?
|
Mice, Nude | 1 | 2012 | 294 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2012 | 258 | 0.020 |
Why?
|
Biphenyl Compounds | 1 | 2012 | 184 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2006 | 1745 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.020 |
Why?
|
Sulfonamides | 1 | 2012 | 141 | 0.020 |
Why?
|
K562 Cells | 1 | 2011 | 44 | 0.020 |
Why?
|
HT29 Cells | 1 | 2011 | 42 | 0.020 |
Why?
|
Peptides | 2 | 2005 | 455 | 0.020 |
Why?
|
Binding Sites | 2 | 2003 | 631 | 0.020 |
Why?
|
Reducing Agents | 1 | 2011 | 5 | 0.020 |
Why?
|
Sepharose | 1 | 2011 | 18 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 2791 | 0.020 |
Why?
|
Glycoside Hydrolases | 1 | 2011 | 25 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2020 | 4848 | 0.020 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 2010 | 24 | 0.020 |
Why?
|
Piperazines | 1 | 2012 | 206 | 0.020 |
Why?
|
Catalysis | 1 | 2011 | 123 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2012 | 567 | 0.020 |
Why?
|
Phospholipids | 1 | 2011 | 108 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2011 | 57 | 0.020 |
Why?
|
Lysosome-Associated Membrane Glycoproteins | 1 | 2010 | 6 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 306 | 0.020 |
Why?
|
Culture Media, Serum-Free | 1 | 2010 | 35 | 0.020 |
Why?
|
Umbilical Veins | 1 | 2010 | 54 | 0.020 |
Why?
|
Cytosol | 1 | 2010 | 123 | 0.020 |
Why?
|
DNA Methylation | 1 | 2011 | 193 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 97 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 492 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
Alkanes | 1 | 2008 | 10 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2011 | 562 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2009 | 73 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 615 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 700 | 0.020 |
Why?
|
Computer Simulation | 1 | 2012 | 706 | 0.020 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2008 | 45 | 0.020 |
Why?
|
Tretinoin | 1 | 2008 | 92 | 0.020 |
Why?
|
Kinetics | 1 | 2010 | 1047 | 0.020 |
Why?
|
Chicken anemia virus | 1 | 2008 | 5 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2010 | 317 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2007 | 84 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2007 | 63 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 95 | 0.020 |
Why?
|
Random Allocation | 1 | 2008 | 442 | 0.020 |
Why?
|
Subcellular Fractions | 1 | 2007 | 92 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2008 | 312 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2011 | 1692 | 0.020 |
Why?
|
Endosomes | 1 | 2006 | 45 | 0.020 |
Why?
|
Caspase 9 | 1 | 2006 | 31 | 0.020 |
Why?
|
Carbon Isotopes | 1 | 2006 | 54 | 0.020 |
Why?
|
Automation | 1 | 2006 | 45 | 0.020 |
Why?
|
Inactivation, Metabolic | 1 | 2006 | 28 | 0.020 |
Why?
|
Thioredoxin Reductase 1 | 1 | 2006 | 3 | 0.020 |
Why?
|
Thioredoxin-Disulfide Reductase | 1 | 2006 | 5 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2006 | 191 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2006 | 41 | 0.020 |
Why?
|
Acylation | 1 | 2006 | 22 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 1040 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 82 | 0.020 |
Why?
|
Adenoviridae | 1 | 2006 | 295 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2006 | 282 | 0.020 |
Why?
|
Solvents | 1 | 2006 | 109 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2010 | 375 | 0.020 |
Why?
|
Drug Combinations | 1 | 2006 | 304 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2006 | 141 | 0.020 |
Why?
|
Phospholipases A2 | 1 | 2005 | 32 | 0.020 |
Why?
|
Insecta | 1 | 2005 | 11 | 0.020 |
Why?
|
Anoikis | 1 | 2005 | 3 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2008 | 493 | 0.020 |
Why?
|
Brefeldin A | 1 | 2005 | 11 | 0.020 |
Why?
|
Pseudopodia | 1 | 2005 | 16 | 0.020 |
Why?
|
Biotinylation | 1 | 2005 | 27 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 376 | 0.020 |
Why?
|
Allosteric Regulation | 1 | 2005 | 58 | 0.020 |
Why?
|
Doxorubicin | 1 | 2006 | 231 | 0.020 |
Why?
|
Fatty Acids | 1 | 2005 | 222 | 0.020 |
Why?
|
Cytoskeleton | 1 | 2005 | 84 | 0.020 |
Why?
|
Cell Separation | 1 | 2005 | 132 | 0.020 |
Why?
|
Aged | 1 | 2020 | 14862 | 0.020 |
Why?
|
Microtubules | 1 | 2005 | 104 | 0.020 |
Why?
|
Glycosylation | 1 | 2005 | 185 | 0.010 |
Why?
|
Holoenzymes | 1 | 2003 | 7 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2006 | 483 | 0.010 |
Why?
|
Silver Staining | 1 | 2003 | 11 | 0.010 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 50 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 88 | 0.010 |
Why?
|
Gene Expression | 1 | 2006 | 770 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2006 | 299 | 0.010 |
Why?
|
Alkalies | 1 | 2003 | 6 | 0.010 |
Why?
|
Actins | 1 | 2005 | 249 | 0.010 |
Why?
|
Telomere | 1 | 2003 | 59 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.010 |
Why?
|
Chromatin | 1 | 2003 | 76 | 0.010 |
Why?
|
Cytoplasm | 1 | 2003 | 155 | 0.010 |
Why?
|
Ultraviolet Rays | 1 | 2003 | 130 | 0.010 |
Why?
|
COS Cells | 1 | 2003 | 155 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 1034 | 0.010 |
Why?
|
Diacylglycerol Kinase | 1 | 2003 | 8 | 0.010 |
Why?
|
Atmospheric Pressure | 1 | 2003 | 8 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2003 | 246 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2003 | 261 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2003 | 357 | 0.010 |
Why?
|
Middle Aged | 1 | 2020 | 21147 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2008 | 824 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 1753 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2002 | 165 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2002 | 231 | 0.010 |
Why?
|
Skin | 1 | 2003 | 451 | 0.010 |
Why?
|
Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|